Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Reactogenicity and Immunogenicity Study of GlaxoSmithKline Biologicals' Pandemic Influenza Vaccine (GSK1119711A) Administered According to Different Vaccination Schedules

NCT00430521 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00430521
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00430521 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Reactogenicity and Immunogenicity Study of GlaxoSmithKline Biologicals' Pandemic Influenza Vaccine (GSK1119711A) Administered According to Different Vaccination Schedules
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Completed
Start date
February 5, 2007
Completion date
October 20, 2008
Enrollment
512 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

influenza, influenza vaccines